Vincent Ribrag, MD

Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Relapsed/Refractory Multiple Myeloma Refractory to an IMiD or Proteasome Inhibitor: Updated Analysis of the Phase 1 ANCHOR Study (OP-104)

Purpose of the Study: Despite recent therapeutic advances, multiple myeloma (MM) remains incurable. Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly c...

Yvonne A. Efebera ;

Miquel Granell ;

Paul G. Richardson ;

Roman Hajek ;

Maria-Victoria Mateos ;

Albert Oriol ;

Jacques Delaunay ;

Katell Le Du ;

Jean-Richard Eveillard ;

Lionel Karlin ;

Vladimir Maisnar ;

Joaquin Martinez-Lopez ;

Maxim Norkin ;

Jan Staub ;

Catriona Byrne ;

Malin Sydvander ;

Enrique M. Ocio ;

Vincent Ribrag , MD;

Ludk Pour ;

10/22/2019

Videos

BTK Inhibitors in Combination With Other Therapies as First-Line Treatment for Patients With Mantle Cell Lymphoma

06/27/2023

Vincent Ribrag , MD;

At the 2023 EHA Congress, Vincent Ribrag, MD, participated in a debate regarding if BTK inhibitors should be combined with other therapies such as bendamustine and rituximab as first-line treatment for mantle cell lymphoma.

At the 2023 EHA Congress,...

06/27/2023

Oncology